All Translational Science articles – Page 6
-
NewsWhy ageing must become central to Parkinson’s research
An international team of scientists is urging researchers to put ageing at the centre of Parkinson’s studies, arguing that it has been overlooked for too long.
-
ArticleAI begins to enter Alzheimer’s drug discovery pipelines
Artificial intelligence is increasingly used to analyse large, multimodal Alzheimer’s datasets and inform target discovery and trial design. A new JPAD special issue highlights how these methods are moving from experimentation towards practical application in drug discovery.
-
NewsHow vaccine structure shapes immune response to HPV tumours
Researchers have discovered that reorganising a single cancer-targeting peptide within a spherical nucleic acid vaccine dramatically boosts the immune system’s ability to attack HPV-driven tumours.
-
NewsLaunaea herb could provide new treatments for peptic ulcers
A herb called Launaea nudicaulis could be used to treat peptic ulcers, with early research suggesting both gastroprotective benefits and potential applications in natural product drug discovery.
-
NewsPromega launches live-cell platform to expand the druggable proteome
A new platform from Promega enables scientists to measure compound binding directly in living cells, helping to translate biochemical hits into more reliable drug discovery decisions.
-
NewsDrug Target Review’s women in STEM
For International Day of Women and Girls in Science, Drug Target Review highlights articles published over the past year that were authored by women, celebrating their contributions to research.
-
NewsNew SHANK3 conditional knockout mouse model launched for PMS research
A new SHANK3 conditional knockout mouse model from InnoSer, CureSHANK and Ozgene has been launched to advance research into Phelan-McDermid syndrome, other neurodevelopmental disorders and the development of new therapies.
-
NewsTangible Scientific launches platform to streamline compound logistics
A new US-based company has launched with the aim of tackling one of the most persistent operational challenges in modern drug discovery – the slow and fragmented handling of physical compounds.
-
NewsHDAC11 protein identified as potential target for Duchenne muscular dystrophy
A new preclinical study has shown that reducing the protein HDAC11 could slow muscle degeneration in Duchenne muscular dystrophy, providing a potential target for future therapies.
-
NewsNew paper warns against phasing out animal testing too quickly
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.
-
NewsCC023 mice reveal how ALS can develop after viral infections
Researchers have discovered a mouse strain that mirrors ALS in humans following a viral infection, offering new insights into how the disease develops, potentially opening new pathways for early diagnosis and drug development.
-
NewsMini-stomach organoids grown to improve disease research
Scientists have grown the first multi-regional “mini-stomach” in the lab, creating a new way to study rare genetic stomach diseases and help to develop new treatments for digestive conditions.
-
NewsBrain discovery could improve drugs targeting amyloid diseases
New research shows the brain can intentionally form amyloids to store memories, challenging decades of thinking about neurodegenerative disease and pointing towards new strategies for drug discovery.
-
NewsCentrifuge technique creates functional bioengineered lymph nodes
Using a straightforward cell stacking method, researchers have regenerated functional lymph nodes, offering a potential long-lasting therapy for secondary lymphedema and creating new opportunities for immunology and oncology drug discovery.
-
NewsTargeting cPLA2 enzyme may reduce brain inflammation in Alzheimer’s
Researchers have identified new drug candidates that selectively target the cPLA2 enzyme, a key driver of brain inflammation linked to Alzheimer’s disease, offering a potential new approach to reducing risk in people with the APOE4 gene.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
-
NewsNew dual CDK approach tackles drug-resistant breast cancer
A new preclinical study suggests that combining next-generation CDK2 inhibitors with existing CDK4/6 therapies could overcome drug resistance in breast cancer, delivering durable tumour control across multiple subtypes.
-
NewsELRIG announces keynote speakers for Cell and Gene Therapy 2026 in Cambridge
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for its inaugural Cell and Gene Therapy 2026 conference, taking place at Hinxton Hall in Cambridge from 9–10 March.
-
NewsHIV drug Maraviroc could be used to slow glioblastoma growth
Researchers have discovered how seemingly supportive brain cells help glioblastoma thrive, whilst identifying an existing HIV drug, Maraviroc, that could be repurposed to slow tumour growth.
-
ArticleTargeting inflammatory cell death to tackle relapse in AML
Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.